Dear Editor

Myeloproliferative neoplasms (MPNs) are categorized on the basis of *BCR/ABL* translocation occurrence as either Philadelphia-positive CML or Philadelphia-negative MPNs (Ph-MPNs). MPNs include polycythaemia vera (PV), essential thrombocythaemia (ET), and primary myelofibrosis (PMF) \[[@B1]\]. The *JAK2*^V617F^ mutation, which is specific for Ph-MPN, occurs in more than 95% PV cases and in approximately 50% ET and PMF cases \[[@B1]\]. The 2008 revision of the WHO classifies MPNs into 2 categories, *BCR/ABL* positive CML and Ph-MPNs, on the basis of the presence or absence of the Philadelphia chromosome \[[@B2]\].

Although the 2008 WHO classification does not include MPNs with more than 1 genetic aberration as a distinct disease entity, some cases with coexistence of *JAK2*^V617F^ mutation and *BCR/ABL* translocation have been recently reported and up to 28 cases have been previously reported \[[@B3]-[@B20]\]. Among these reports, the majority of the patients either had pre-existing *BCR/ABL*-positive CML and developed *JAK2*^V617F^ mutation while undergoing tyrosine kinase inhibitor treatment \[[@B4]-[@B7]\] or developed *BCR/ABL*-positive CML with a pre-existing *JAK2*^V617F^ mutation-positive MPN \[[@B8]-[@B12]\]. In contrast, a small number of patients showed simultaneous occurrence of both *JAK2*^V617F^ mutation and *BCR/ABL* translocation, with a CML phenotype in the bone marrow (BM) with development of symptoms or morphology associated with *JAK2*^V617F^ mutation, and with MPN only after imatinib treatment \[[@B3], [@B6], [@B13]-[@B15]\]. We report 2 MPN cases that were simultaneously positive for both *JAK2*^V617F^ mutation and *BCR/ABL* translocation and that did not acquire the CML phenotype during hydroxyurea (Korea United Pharm, Seoul, Korea) treatment.

Case 1 was a 36-yr-old man who was admitted in November 2009 with severe thrombocytosis. The patient\'s hemogram results at admission were as follows: white blood cells, 9.4×10^9^/L, Hb, 13.8 g/dL, and platelets, 830×10^9^/L. The peripheral blood smear (PBS) and BM biopsy revealed a marked increase in the platelet and the clustered megakaryocyte numbers (9.2/high power field) without evidence of dysplasia. Allele-specific PCR for *JAK2*^V617F^ mutation detection and reverse-transcriptase PCR (RT-PCR) for *BCR/ABL* fusion transcript detection using custom-designed primers was performed. The PCR and the RT-PCR analyses showed that the patient was positive for *JAK2*^V617F^ heterozygous mutation and the *BCR/ABL* fusion transcript (b3a2 type), respectively.

Subsequently, the *JAK2*^V617F^ mutation allele burden was quantified by real-time quantitative PCR using JAK2 Muta*Quant*™ (Ipsogen, Marseille, France). The *JAK2*^V617F^ mutation allele burden was calculated as the percentage of the V617F copy number to the sum of V617F and wild-type copy number. The *JAK2*^V617F^ mutation allele burden was quantified to be 27.91% (7,200/25,800) at diagnosis. The major *BCR/ABL* fusion transcripts quantitation was also performed by real-time PCR using the LightCycler t(9;22) Quantification kit (Roche Diagnostics, Mannheim, Germany) and the normalized copy number (NCN) was 0.02 at diagnosis. The patient\'s karyotype was determined to be 46,XY \[[@B20]\]; however, his interphase FISH analysis result was nuc ish(ABL1x3,BCRx2)(ABL1 con BCRx1)\[61/200\], representing cryptic *BCR/ABL* fusion on der(22)t(9;22) in 30.5% of the total cells.

Thus, on the basis of these findings, the patient was diagnosed to have ET with a major *BCR/ABL* fusion transcript. The patient was treated with hydroxyurea and the initial response during the first year of treatment was promising (*BCR/ABL* fusion transcript maintained in the range of 0.005 NCN to 0.01 NCN). However, despite continuing treatment, the number of *BCR/ABL* fusion transcripts increased to 5.0 NCN in the second year of follow-up, which indicated treatment failure. Interestingly, the patient did not show morphological evidence of CML during the follow-up period.

Case 2 was a 58-yr-old man diagnosed with leukocytosis and splenomegaly on admission. The patient\'s hemogram results at admission were as follows: white blood cells, 19.7×10^9^/L, Hb, 13.0 g/dL, and platelets, 285×10^9^/L. The PBS showed an occasional presence of tear-drop cells and immature granulocytes with blasts ([Fig. 1A](#F1){ref-type="fig"}). The BM biopsy showed extensive myelofibrosis (grade 2-3) with a cellularity of 90% and an increased number of dysplastic megakaryocytes ([Fig. 1B](#F1){ref-type="fig"}). The myelofibrosis was demonstrated by the reticulin silver stain ([Fig. 1C](#F1){ref-type="fig"}). At diagnosis, the *JAK2*^V617F^ mutation analysis showed a heterozygous mutation ([Fig. 1D](#F1){ref-type="fig"}) and the *JAK2*^V617F^ mutation allele burden was quantified to be 69.66% (2,640/3,790). The RT-PCR analysis revealed the presence of *BCR/ABL* fusion transcript (b3a2 type) ([Fig. 1E](#F1){ref-type="fig"}). The patient\'s karyotype was determined to be 46,XY, t(9;22)(q34;q11.2)\[4\]/46,XY\[16\]. The quantification result for the major *BCR/ABL* fusion transcript in BM was found to be 1.0 NCN at diagnosis, which was 50-fold higher than that of case 1. The patient was treated with hydroxyurea for 6 months. However, the *BCR/ABL* fusion transcript levels remained at the levels at diagnosis (1.0-1.6 NCN). Similar to the findings for case 1, the morphological evidence of CML was not evident during hydroxyurea treatment. The drug treatment was changed to dasatinib and after 7 months of dasatinib treatment the patient did not show conversion, which was indicative of successful treatment.

Of the previously reported 28 cases with both *JAK2*^V617F^ mutation and *BCR/ABL* translocation, 15 patients had *BCR/ABL*-positive CML and acquired a *JAK2*^V617F^-positive MPN phenotype after tyrosine kinase inhibitor treatment. Although 4 out of the 15 patients were diagnosed with CML and were shown to possess *JAK2*^V617F^ mutation, 3 of the 4 patients did not show a morphology associated with *JAK2*^V617F^ mutation-positive MPN until after treatment with imatinib. In contrast, 9 of the 28 patients showed *JAK2*^V617F^ mutation-positive MPN phenotype at initial diagnosis and developed *BCR/ABL*-positive CML during hydroxyurea treatment. Finally, at initial diagnosis, 4 patients showed mixed phenotype associated with both *BCR/ABL*-positive CML and *JAK2*^V617F^ mutation-positive MPN \[[@B3]\].

In recent studies, 2 hypotheses have been proposed to explain the coexistence of both *BCR/ABL* translocation and *JAK2*^V617F^ mutation in some patients. The first hypothesis which has been favored in the several literatures proposes that a single clone possesses one aberration and the patient\'s phenotype (e.g. CML feature) is dependent on the dominant clone (e.g. *BCR/ABL* translocation positive) which is determined by the selective pressure exerted by the specific treatment (e.g. hydoxyurea) prescribed for the other clone (e.g. *JAK2*^V617F^ mutation positive) \[[@B4]-[@B12]\]. The second hypothesis proposes that a single clone concurrently possesses both the *BCR/ABL* translocation and *JAK2*^V617F^ mutation \[[@B3], [@B13]-[@B15]\]. This hypothesis was supported by a recent study, which reported that the *BCR/ABL* translocation occurred in a pre-existing *JAK2*^V617F^ mutation-positive clone \[[@B18]\]. The data obtained in this study supports the second hypothesis as shown by the detection of concurrent *JAK2*^V617F^ mutation and *BCR/ABL* translocation at the initial diagnosis of MPN, and the lack of phenotype switch, especially to the CML phenotype, during hydroxyurea treatment. Hence, a comprehensive molecular genetic analysis is needed to elucidate the pathogenesis of these hematological chimeras.

In addition, the 2 patients showed different outcomes according to both the initial level of *BCR/ABL* fusion transcripts and the introduction of a tyrosine kinase inhibitor during the hydroxyurea treatment. The patient with low initial *BCR/ABL* fusion transcript levels experienced a relatively good initial response to hydroxyurea treatment, although the treatment failed 2 years later. In contrast, the patient with high *BCR/ABL* fusion transcript levels did not initially respond well to hydroxyurea treatment, but a dramatic response was achieved after a treatment change to dasatinib. On the basis of these findings, we speculate that treatment with a tyrosine kinase inhibitor can be effective and therefore recommend this approach in *JAK2*^V617F^-positive MPN patients with a concurrent *BCR/ABL* translocation, particularly if the initial *BCR/ABL* fusion transcript level is high.

In conclusion, we report 2 cases of MPN with concurrent *JAK2*^V617F^ mutation and *BCR/ABL* translocation without CML phenotype acquisition during the hydroxyurea treatment. Treatment with tyrosine kinase inhibitors can be effective, particularly if the initial *BCR/ABL* fusion transcript level is high in these patients. Further molecular genetic analysis is needed to elucidate the pathogenesis of these hematological chimeras.
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![The hematological and molecular characteristics of case 2. (A) A peripheral blood smear revealed tear-drop cells, immature granulocytes, and blasts (Wright stain, ×400). (B) The patient\'s bone marrow biopsy showed extensive myelofibrosis (H&E stain, ×100), demonstrated by reticulin silver stain (C, ×100) with cellularity of 90% and increased dysplastic megakaryocytes. (D) Mutational analysis of *JAK2*^V617F^ revealed bands that corresponded to both the mutant and wild-type *JAK2* (sized 299 bp and 229 bp, respectively). (E) Along with the myeloproliferative neoplasms (MPNs) diagnosis tests, reverse transcriptase (RT)-PCR analysis of *BCR/ABL* fusion transcripts was performed and a single 305-bp band, representing the major *BCR/ABL* translocation (b3a2 type), was obtained.](alm-33-229-g001){#F1}
